Alivus Life Sciences Ltd vs Bacil Pharma Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 03, 2026

Key Highlights

The Latest Trading Price of Alivus Life Sciences Ltd is ₹ 1046 as of 13 Apr 15:30 . The P/E Ratio of Alivus Life Sciences Ltd changed from 13.4 on March 2022 to 27.2 on March 2025 . This represents a CAGR of 19.36% over 4 yearsThe P/E Ratio of Bacil Pharma Ltd changed from 146.5 on March 2025 to 146.5 on March 2025 . This represents a CAGR of 0.00% over 1 years The Market Cap of Alivus Life Sciences Ltd changed from ₹ 5624 crore on March 2022 to ₹ 13229 crore on March 2025 . This represents a CAGR of 23.84% over 4 yearsThe Market Cap of Bacil Pharma Ltd changed from ₹ 1.84 crore on March 2021 to ₹ 60.99 crore on March 2025 . This represents a CAGR of 101.41% over 5 years The revenue of Alivus Life Sciences Ltd for the Dec '25 is ₹ 686.82 crore as compare to the Sep '25 revenue of ₹ 602.7 crore. This represent the growth of 13.96% The revenue of Bacil Pharma Ltd for the Dec '25 is ₹ 0.06 crore as compare to the Sep '25 revenue of ₹ 0.05 crore. This represent the growth of 20% The ebitda of Alivus Life Sciences Ltd for the Dec '25 is ₹ 219.54 crore as compare to the Sep '25 ebitda of ₹ 193.89 crore. This represent the growth of 13.23% The ebitda of Bacil Pharma Ltd for the Dec '25 is ₹ 0.04 crore as compare to the Sep '25 ebitda of ₹ 0.02 crore. This represent the growth of 100% The net profit of Alivus Life Sciences Ltd changed from ₹ 111.48 crore to ₹ 150.26 crore over 7 quarters. This represents a CAGR of 18.60% The net profit of Bacil Pharma Ltd changed from ₹ -0.03 crore to ₹ 0.04 crore over 7 quarters. This represents a CAGR of NaN% The Dividend Payout of Alivus Life Sciences Ltd changed from 61.46 % on March 2022 to 12.62 % on March 2025 . This represents a CAGR of -32.68% over 4 yearsThe Dividend Payout of Bacil Pharma Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Alivus Life Sciences Ltd

Alivus Life Sciences Limited was initially established as 'Zorg Laboratories Private Limited', on June 23, 2011 and was granted the Certificate of Incorporation by the Registrar of Companies, Maharashtra in Pune.
Subsequently, the Company was acquired by Glenmark Pharmaceuticals Limited through a Share Purchase Agreement dated 04 July 2018 and the name of the Company was changed to Glenmark Life Sciences Private Limited' and a fresh Certificate of Incorporation dated 28 August 2018 was issued by the RoC. The name of the Company has now changed to 'Alivus Life Sciences Limited' on January 20, 2025. Nirma Limited is a Subsidiary of the Company.
The Company is engaged in the business of development, manufacture and marketing of Active Pharmaceutical Ingredients(APIs). In 2001, Glenmark Pharmaceuticals established its API business.

About Bacil Pharma Ltd

Incorporated as a private limited company in Maharashtra in May '87, Bacil Pharma (BPL) was converted into a public limited company in Oct.'90.
The main business activity of the Company is Pharmaceutical. Bal Pharma is a fully integrated and leading Indian pharmaceutical company specialized in Prescription drugs, Branded Formulations, APIs, Generic & OTC products, Intravenous Infusions and Bulk Drugs.
Domestic operations are spread across pan India.
The company has strong field force of 500 plus, spread over various States and Districts.
It has a strong distribution set up, with Super Stockist in all the States and stockists for retail coverage.

FAQs for the comparison of Alivus Life Sciences Ltd and Bacil Pharma Ltd

Which company has a larger market capitalization, Alivus Life Sciences Ltd or Bacil Pharma Ltd?

Market cap of Alivus Life Sciences Ltd is 12,733 Cr while Market cap of Bacil Pharma Ltd is 81 Cr

What are the key factors driving the stock performance of Alivus Life Sciences Ltd and Bacil Pharma Ltd?

The stock performance of Alivus Life Sciences Ltd and Bacil Pharma Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Alivus Life Sciences Ltd and Bacil Pharma Ltd?

As of May 3, 2026, the Alivus Life Sciences Ltd stock price is INR ₹1037.5. On the other hand, Bacil Pharma Ltd stock price is INR ₹56.95.

How do dividend payouts of Alivus Life Sciences Ltd and Bacil Pharma Ltd compare?

To compare the dividend payouts of Alivus Life Sciences Ltd and Bacil Pharma Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.